171 related articles for article (PubMed ID: 28509133)
1. Denosumab for treatment of immobilization-related hypercalcemia in a patient with end-stage renal disease.
Uehara A; Yazawa M; Kawata A; Hachisuka R; Shibagaki Y
CEN Case Rep; 2017 May; 6(1):111-114. PubMed ID: 28509133
[TBL] [Abstract][Full Text] [Related]
2. Use of high-dose denosumab in the management of immobilization-related hypercalcemia in an end-stage renal disease patient on hemodialysis: A case report and review of the literature.
Zaitoun MF; Al-Alsheikh KA; Elnazer W
Clin Nephrol; 2021 Dec; 96(6):353-356. PubMed ID: 34605398
[TBL] [Abstract][Full Text] [Related]
3. Denosumab for the treatment of bisphosphonate resistant hypercalcemia in a hemodialysis patient.
Dahmani O; Sophoclis C; Kebir M; Bouguern D; Sakho A; Demarchi P
Saudi J Kidney Dis Transpl; 2017; 28(1):154-157. PubMed ID: 28098117
[TBL] [Abstract][Full Text] [Related]
4. Using denosumab to treat immobilization hypercalcemia in a post-acute care patient.
Booth KA; Hays CI
J Clin Endocrinol Metab; 2014 Oct; 99(10):3531-5. PubMed ID: 25033064
[TBL] [Abstract][Full Text] [Related]
5. Use of denosumab to treat refractory hypercalcemia in a peritoneal dialysis patient with immobilization and tertiary hyperparathyroidism.
Pratt RM; West ML; Tennankore KK
Perit Dial Int; 2020 Jan; 40(1):103-106. PubMed ID: 32063140
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment with denosumab for two cases with hypercalcemia due to vitamin D intoxication and associated acute kidney injury.
Barth K; Sedivy M; Lindner G; Schwarz C
CEN Case Rep; 2022 Feb; 11(1):141-145. PubMed ID: 34515963
[TBL] [Abstract][Full Text] [Related]
7. Denosumab in hypercalcemia of malignancy: a case series.
Dietzek A; Connelly K; Cotugno M; Bartel S; McDonnell AM
J Oncol Pharm Pract; 2015 Apr; 21(2):143-7. PubMed ID: 24415364
[TBL] [Abstract][Full Text] [Related]
8. Symptomatic hypercalcemia of immobilization in a patient with end-stage renal disease.
Gopal H; Sklar AH; Sherrard DJ
Am J Kidney Dis; 2000 May; 35(5):969-72. PubMed ID: 10793036
[TBL] [Abstract][Full Text] [Related]
9. Immobilization-induced hypercalcemia in a patient with renal failure.
Gandhi A; Mortensen M; Sunny S; Techathaveewat P; Targovnik J; Alsayed M
Endocrinol Diabetes Metab Case Rep; 2021 Oct; 2021():. PubMed ID: 34612208
[TBL] [Abstract][Full Text] [Related]
10. Immobilization-related hypercalcemia after renal failure in burn injury.
Peralta MC; Gordon DL
Endocr Pract; 2002; 8(3):213-6. PubMed ID: 12113635
[TBL] [Abstract][Full Text] [Related]
11. Contrasting PTH Response of Denosumab Use in Dialysis Patients: A Report of 2 Cases.
Jang SM; Anam S; Pringle T; Lahren P; Infante S
Pharmacy (Basel); 2020 Apr; 8(2):. PubMed ID: 32244607
[TBL] [Abstract][Full Text] [Related]
12. Severe hypocalcemia following denosumab injection in a hemodialysis patient.
McCormick BB; Davis J; Burns KD
Am J Kidney Dis; 2012 Oct; 60(4):626-8. PubMed ID: 22854051
[TBL] [Abstract][Full Text] [Related]
13. Case report: Denosumab-associated acute heart failure in patients with cardiorenal insufficiency.
Xing Y; Ju S; Sun M; Xiang S
Front Endocrinol (Lausanne); 2022; 13():970571. PubMed ID: 36187135
[TBL] [Abstract][Full Text] [Related]
14. Too Much of a Good Thing: Severe Hypercalcemia Presenting with Lethargy and Kidney Failure.
Hofmann P; Carta AF; Trachsel C; Helmchen BM
Praxis (Bern 1994); 2024 Apr; 113(4):106-110. PubMed ID: 38779795
[TBL] [Abstract][Full Text] [Related]
15. Looking at calcimimetics impact on hypercalcemia of immobilization: hypotheses and a case study.
Roueff S; Saint Georges M; Chuong VT; Abbassi A; Guédon C; de Vernejoul MC; Ureña Torres P
Hemodial Int; 2006 Jan; 10(1):29-34. PubMed ID: 16441824
[TBL] [Abstract][Full Text] [Related]
16. Rapid progression of vascular and soft tissue calcification while being managed for severe and persistent hypocalcemia induced by denosumab treatment in a patient with multiple myeloma and chronic kidney disease.
Ueki K; Yamada S; Tsuchimoto A; Tokumoto M; Kumano T; Kitazono T; Tsuruya K
Intern Med; 2015; 54(20):2637-42. PubMed ID: 26466702
[TBL] [Abstract][Full Text] [Related]
17. [Esophageal Cancer Initially Presenting as Severe Paraneoplastic Hypercalcemia Requiring Hemodialysis].
Ahn HS; Yun JM; Lee YB; Ko YM; Lee JE; Won HS; Kim SS; Kim YO
Korean J Gastroenterol; 2015 Jun; 65(6):361-5. PubMed ID: 26087691
[TBL] [Abstract][Full Text] [Related]
18. SEVERE, PROLONGED, DENOSUMAB-INDUCED HYPOCALCEMIA WITH RECOVERY AFTER 111 DAYS OF HIGH-DOSE CALCIUM SUPPLEMENTATION.
McCaleb RV; Johnson JT
AACE Clin Case Rep; 2019; 5(1):e82-e85. PubMed ID: 31967007
[TBL] [Abstract][Full Text] [Related]
19. Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone.
Gossai N; Hilgers MV; Polgreen LE; Greengard EG
Pediatr Blood Cancer; 2015 Jun; 62(6):1078-80. PubMed ID: 25556556
[TBL] [Abstract][Full Text] [Related]
20. Use of denosumab in a dialysis patient with bone metastases from breast cancer and hepatorenal polycystic disease: a case report.
Quiroga García V; Cirauqui Cirauqui B; Tobey Robaina L; López Sisamon D; Hardy-Werbin M; Blanca AB; Margelí Vila M
Anticancer Drugs; 2016 Jun; 27(5):464-9. PubMed ID: 26813866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
